Individuals involved in the criminal-legal system, particularly those incarcerated in prisons, are highly impacted by the opioid epidemic. Individuals from rural areas who are incarcerated may face disparate access to naloxone, the agent used to reverse opioid-induced respiratory depression. This objective of this study was to describe pre-incarceration possession of naloxone among rural and urban individuals incarcerated in state prisons.
Methods:
As part of the Geographic variation in Addiction Treatment Experiences study, data were collected from adults incarcerated and released from 14 Kentucky state prisons. Eligible individuals had a history of opioid use disorder and had participated in prison-based substance use disorder treatment. Structured surveys were conducted from June 2021 to March 2024 (n = 393). Two dependent variables, lifetime and recent possession of naloxone in the 6 months prior to incarceration, were measured. Then, 2 multivariate logistic regression models were estimated to examine associations between rurality, demographic characteristics, and opioid-related measures on these 2 dependent variables.
Results:
About 56% of the sample had personally experienced opioid overdose. Prior to incarceration, 47% had ever possessed naloxone and 36% reported recent possession of naloxone. Rural individuals were significantly less likely than urban individuals to report lifetime naloxone possession (odds ratio [OR] = 0.58, 95% CI = 0.35-0.96, P = .04) and recent naloxone possession (OR = 0.56, 95% CI = 0.33-0.97, P = .04).
Conclusions:
In this sample recruited from Kentucky prisons, many individuals had experienced an overdose prior to incarceration, but few had naloxone. Given the significant disparities between rural and urban individuals in naloxone possession prior to incarceration, greater access to naloxone at prison release and in communities is urgently needed.
SlavovaSQuesinberryDHargroveS, et al. Trends in drug overdose mortality rates in Kentucky, 2019-2020. JAMA Netw Open. 2021;4(7):e2116391. doi:10.1001/jamanetworkopen.2021.16391
2.
FriedmanJAkreS.COVID-19 and the drug overdose crisis: uncovering the deadliest months in the United States, January-July 2020. Am J Public Health. 2021;111(7):1284-1291. doi:10.2105/AJPH.2021.306256
3.
FlorenceCLuoFRiceK.The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017. Drug Alcohol Depend. 2021;218:108350. doi:10.1016/j.drugalcdep.2020.108350
4.
GrellaCEOstlieEScottCKDennisMLCarnevaleJWatsonDP.A scoping review of factors that influence opioid overdose prevention for justice-involved populations. Subst Abuse Treat Prev Policy. 2021;16(1):19. doi:10.1186/s13011-021-00346-1
5.
KinnerSAMilloyMJWoodEQiJZhangRKerrT.Incidence and risk factors for non-fatal overdose among a cohort of recently incarcerated illicit drug users. Addict Behav. 2012;37(6):691-696. doi:10.1016/j.addbeh.2012.01.019
6.
GanWQKinnerSANichollsTL, et al. Risk of overdose-related death for people with a history of incarceration. Addiction. 2021;116(6):1460-1471. doi:10.1111/add.15293
7.
MooreEWinterRIndigDGreenbergDKinnerSA.Non-fatal overdose among adult prisoners with a history of injecting drug use in two Australian states. Drug Alcohol Depend. 2013;133(1):45-51. doi:10.1016/j.drugalcdep.2013.06.001
8.
WinterRJStooveMDegenhardtL, et al. Incidence and predictors of non-fatal drug overdose after release from prison among people who inject drugs in Queensland, Australia. Drug Alcohol Depend. 2015;153:43-49. doi:10.1016/j.drugalcdep.2015.06.011
9.
LarochelleMRBernsteinRBernsonD, et al. Touchpoints—opportunities to predict and prevent opioid overdose: a cohort study. Drug Alcohol Depend. 2019;204:107537. doi:10.1016/j.drugalcdep.2019.06.039
10.
MerrallELKariminiaABinswangerIA, et al. Meta-analysis of drug-related deaths soon after release from prison. Addiction. 2010;105(9):1545-1554. doi:10.1111/j.1360-0443.2010.02990.x
11.
BuktenAStavsethMRSkurtveitSTverdalAStrangJClausenT.High risk of overdose death following release from prison: variations in mortality during a 15-year observation period. Addiction. 2017;112(8):1432-1439. doi:10.1111/add.13803
12.
McDonaldRStrangJ.Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction. 2016;111(7):1177-1187. doi:10.1111/add.13326
13.
NaumannRBDurranceCPRanapurwalaSI, et al. Impact of a community-based naloxone distribution program on opioid overdose death rates. Drug Alcohol Depend. 2019;204:107536. doi:10.1016/j.drugalcdep.2019.06.038
14.
Moustaqim-BarretteADhillonDNgJ, et al. Take-home naloxone programs for suspected opioid overdose in community settings: a scoping umbrella review. BMC Public Health. 2021;21(1):597. doi:10.1186/s12889-021-10497-2
15.
RazaghizadAWindleSBFilionKB, et al. The effect of overdose education and naloxone distribution: an umbrella review of systematic reviews. Am J Public Health. 2021;111(8):e1-e12. doi:10.2105/AJPH.2021.306306
16.
BennettTHollowayK.The impact of take-home naloxone distribution and training on opiate overdose knowledge and response: an evaluation of the THN Project in Wales. Drugs Educ Prev Policy. 2012;19(4):320-328.
17.
ClarkAKWilderCMWinstanleyEL.A systematic review of community opioid overdose prevention and naloxone distribution programs. J Addict Med. 2014;8(3):153-163. doi:10.1097/ADM.0000000000000034
18.
BirdSMMcAuleyAPerrySHunterC.Effectiveness of Scotland’s National Naloxone Programme for reducing opioid-related deaths: a before (2006-10) versus after (2011-13) comparison. Addiction. 2016;111(5):883-891. doi:10.1111/add.13265
19.
BirdSMMcAuleyAMunroAHutchinsonSJTaylorA.Prison-based prescriptions aid Scotland’s National Naloxone Programme. Lancet. 2017;389(10073):1005-1006. doi:10.1016/S0140-6736(17)30656-6
BarocasJABakerLHullSJStokesSWestergaardRP.High uptake of naloxone-based overdose prevention training among previously incarcerated syringe-exchange program participants. Drug Alcohol Depend. 2015;154:283-286. doi:10.1016/j.drugalcdep.2015.06.023
22.
CurtisMDietzePAitkenC, et al. Acceptability of prison-based take-home naloxone programmes among a cohort of incarcerated men with a history of regular injecting drug use. Harm Reduct J. 2018;15(1):48. doi:10.1186/s12954-018-0255-5
23.
DavidsonPJWagnerKDTokarPLScholarS.Documenting need for naloxone distribution in the Los Angeles County jail system. Addict Behav. 2019;92:20-23. doi:10.1016/j.addbeh.2018.12.017
24.
WengerLDShowalterDLambdinB, et al. Overdose education and naloxone distribution in the San Francisco county jail. J Correct Health Care. 2019;25(4):394-404. doi:10.1177/1078345819882771
25.
HooverDBKorthuisPTWaddellEN, et al. Recent incarceration, substance use, overdose, and service use among people who use drugs in rural communities. JAMA Netw Open. 2023;6(11):e2342222. doi:10.1001/jamanetworkopen.2023.42222
26.
MoodyLSatterwhiteEBickelWK.Substance use in rural Central Appalachia: current status and treatment considerations. Rural Ment Health. 2017;41(2):123-135. doi:10.1037/rmh0000064
27.
DunnKEBarrettFSYepez-LaubachC, et al. Opioid overdose experience, risk behaviors, and knowledge in drug users from a rural versus an urban setting. J Subst Abuse Treat. 2016;71:1-7. doi:10.1016/j.jsat.2016.08.006
28.
SissonMLMcMahanKBChichesterKRGalbraithJWCropseyKL.Attitudes and availability: a comparison of naloxone dispensing across chain and independent pharmacies in rural and urban areas in Alabama. Int J Drug Policy. 2019;74:229-235. doi:10.1016/j.drugpo.2019.09.021
29.
NguyenJLGilbertLRBeasleyL, et al. Availability of naloxone at rural Georgia pharmacies, 2019. JAMA Netw Open. 2020;3(2):e1921227. doi:10.1001/jamanetworkopen.2019.21227
30.
OserCBBattyEBootyM, et al. Social ecological factors and medication treatment for opioid use disorder among justice-involved rural and urban persons: the Geographic variation in Addiction Treatment Experiences (GATE) longitudinal cohort study protocol. BMJ Open. 2023;13(3):e066068. doi:10.1136/bmjopen-2022-066068
LancasterKECooperHLFBrowningCRMalvestuttoCDBridgesJFPYoungAM.Syringe service program utilization, barriers, and preferences for design in rural Appalachia: differences between men and women who inject drugs. Subst Use Misuse. 2020;55(14):2268-2277. doi:10.1080/10826084.2020.1800741
RoystonP.Multiple imputation of missing values. Stata J. 2004;4(3):227-241.
36.
RoystonP.Multiple imputation of missing values: update. Stata J. 2005;5(2):188-201.
37.
RoystonP.Multiple imputation of missing values: update of ice. Stata J. 2005;5(4):527-536.
38.
WhiteIRRoystonPWoodAM.Multiple imputation using chained equations: issues and guidance for practice. Stat Med. 2011;30(4):377-399. doi:10.1002/sim.4067
39.
EzellJMWaltersSFriedmanSR, et al. Stigmatize the use, not the user? Attitudes on opioid use, drug injection, treatment, and overdose prevention in rural communities. Soc Sci Med. 2021;268:113470. doi:10.1016/j.socscimed.2020.113470
40.
DavisAStringerKLDrainoniML, et al. Community-level determinants of stakeholder perceptions of community stigma toward people with opioid use disorders, harm reduction services and treatment in the HEALing Communities Study. Int J Drug Policy. 2023;122:104241. doi:10.1016/j.drugpo.2023.104241
41.
WhippleCRKaynakOKruisNESaylorEBonnevieEKensingerWS.Opioid use disorder stigma and support for harm reduction in rural counties. Subst Use Misuse. 2023;58(14):1818-1828. doi:10.1080/10826084.2023.2250434
42.
FadanelliMCloudDHIbragimovU, et al. People, places, and stigma: a qualitative study exploring the overdose risk environment in rural Kentucky. Int J Drug Policy. 2020;85:102588. doi:10.1016/j.drugpo.2019.11.001
43.
TofighiBMartinoDLekasHMWilliamsSZBlauCLewisCF.Scaling opioid overdose prevention and naloxone dispensation among rural and small metro area pharmacists: findings from a qualitative study. J Subst Use. 2023;28(4):568-573. doi:10.1080/14659891.2022.2070877
44.
StoneRHHurSYoungHN.Assessment of naloxone availability in Georgia community pharmacies. J Am Pharm Assoc. 2020;60(2):357-361. doi:10.1016/j.japh.2019.11.003
45.
AlruwailiAAlanazyARM. Prehospital time interval for urban and rural emergency medical services: a systematic literature review. Healthcare. 2022;10(12):2391. doi:10.3390/healthcare10122391
46.
SmithAPLangJCanedoC, et al. Drug overdose deaths in Kentucky, 2019-2024: are we back to pre-COVID-19 levels?Inj Epidemiol. 2025;12(1):51. doi:10.1186/s40621-025-00608-7
47.
Perez-FigueroaREOserCBMalinowskaK.Access to naloxone in underserved communities. BMJ. 2023;381:894. doi:10.1136/bmj.p894
48.
KnudsenHKFreemanPROylerDROserCBWalshSL.Scaling up overdose education and naloxone distribution in Kentucky: adoption and reach achieved through a “hub with many spokes” model. Addict Sci Clin Pract. 2023;18(1):72. doi:10.1186/s13722-023-00426-6
49.
OylerDRKnudsenHKOserCB, et al. Equity of overdose education and naloxone distribution provided in the Kentucky HEALing Communities Study. Drug Alcohol Depend Rep. 2024;10:100207. doi:10.1016/j.dadr.2023.100207
50.
OserCBMcGladreyMOylerDR, et al. Description of implementing a mail-based overdose education and naloxone distribution program in community supervision settings during COVID-19. J Subst Use Addict Treat. 2025;170:209618. doi:10.1016/j.josat.2024.209618
51.
TaylorJLLasserKE.Intranasal naloxone for opioid overdose. JAMA. 2024;331(3):250-251. doi:10.1001/jama.2023.23248
52.
Gonzalez UtrillaMChesneyENealeJ, et al. Naloxone dosing in the era of synthetic opioids: applying the Goldilocks principle. Addiction. 2025;120(11):2165-2172. doi:10.1111/add.70060
53.
LemenPMGarrettDPThompsonEAhoMVasquezCParkJN.High-dose naloxone formulations are not as essential as we thought. Harm Reduct J. 2024;21(1):93. doi:10.1186/s12954-024-00994-z
54.
BinswangerIANguyenAPMorenoffJDXuSHardingDJ.The association of criminal justice supervision setting with overdose mortality: a longitudinal cohort study. Addiction. 2020;115(12):2329-2338. doi:10.1111/add.15077
55.
WinhusenTWalleyAFanucchiLC, et al. The Opioid-overdose Reduction Continuum of Care Approach (ORCCA): evidence-based practices in the HEALing Communities Study. Drug Alcohol Depend. 2020;217:108325. doi:10.1016/j.drugalcdep.2020.108325
56.
PearceLAMathanyLRothonDKuoMBuxtonJA.An evaluation of Take Home Naloxone program implementation in British Columbian correctional facilities. Int J Prison Health. 2019;15(1):46-57. doi:10.1108/IJPH-12-2017-0058
57.
SondhiARyanGDayE.Stakeholder perceptions and operational barriers in the training and distribution of take-home naloxone within prisons in England. Harm Reduct J. 2016;13:5. doi:10.1186/s12954-016-0094-1
58.
MeadeAMBirdSMStrangJ, et al. Methods for delivering the UK’s multi-centre prison-based naloxone-on-release pilot randomised trial (N-ALIVE): Europe’s largest prison-based randomised controlled trial. Drug Alcohol Rev. 2018;37(4):487-498. doi:10.1111/dar.12592
59.
ZuckerHAnnucciAJStancliffSCataniaH.Overdose prevention for prisoners in New York: a novel program and collaboration. Harm Reduct J. 2015;12:51. doi:10.1186/s12954-015-0084-8
60.
OserCBMcGladreyMBootyM, et al. Rapid jail-based implementation of overdose education and naloxone distribution (OEND) in response to the COVID-19 pandemic. Health Justice. 2024;12:27. doi:10.1186/s40352-024-00283-8
61.
LipiraLLeichtlingGCookRR, et al. Predictors of having naloxone in urban and rural Oregon findings from NHBS and the OR-HOPE study. Drug Alcohol Depend. 2021;227:108912. doi:10.1016/j.drugalcdep.2021.108912
62.
ZinsliKABanta-GreenCJWhitesideLK, et al. Trends and correlates of naloxone possession and use among people who inject drugs in Seattle, Washington. Int J Drug Policy. 2023:104272. doi:10.1016/j.drugpo.2023.104272
63.
HarrisSJ.An early implementation analysis of syringe services programs in Kentucky: barriers and facilitators identified by program operators and local officials. AIDS Behav. 2023;27(4):1248-1258. doi:10.1007/s10461-022-03861-9
64.
BattyEJIbragimovUFadanelliM, et al. A qualitative analysis of rural syringe service program fidelity in Appalachian Kentucky: staff and participant perspectives. J Rural Health. 2023;39(2):328-337. doi:10.1111/jrh.12715
65.
DaytonLGicquelaisRETobinK, et al. More than just availability: who has access and who administers take-home naloxone in Baltimore, MD. PLoS One. 2019;14(11):e0224686. doi:10.1371/journal.pone.0224686
66.
SibleyALKleinECooperHLF, et al. The relationship between felt stigma and non-fatal overdose among rural people who use drugs. Harm Reduct J. 2024;21(1):77. doi:10.1186/s12954-024-00988-x
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
